Adjusted EBITDA loss was C$0.6M in Q3 compared to C$0.3M in 3Q23. Cash and cash equivalents decreased to C$1M at the end of Q3 versus C$1.5M at the end of fiscal 2023. “As we close this transformative chapter with the recently-completed sale of CannMart, Lifeist can now fully focus on our core mission of delivering science-based nutraceuticals that promote wellness and longevity,” said Meni Morim, CEO of Lifeist. “Although revenues in this segment remain modest, we are taking strategic steps to accelerate growth, optimize our operations, and bring innovative products to market. Our team is committed to building a strong foundation for sustainable success, and I’m confident that we are on the right path toward creating long-term value for our shareholders.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LFSWF:
- Lifeist Wellness Shifts Focus After Ending Agreement
- Lifeist Wellness announces conclusion of consulting agreement with Singular
- Lifeist Wellness Announces Executive Changes, Refocuses Strategy
- Lifeist Wellness announces CEO Morim to reduce involvement in company
- Lifeist Wellness Subsidiary Mikra Revamps Website
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
